On October 19, 2026, Veradermics (NYSE: MANE) announced positive topline results from Study ‘304’ — the confirmatory Phase 3 trial […]
Veradermics’ second-quarter 2026 report (August 11, 2026) delivered three pieces of news that matter for anyone tracking VDPHL01 — the
Veradermics, Incorporated (NYSE: MANE) has reported positive topline results from the female treatment arms of Study ‘207’, an open-label Phase
Update (October 19, 2026): The first milestone on this roadmap is done. Study ‘304’ met every primary and secondary endpoint
Update (October 19, 2026): Confirmatory Phase 3 Study ‘304’ has now read out positive as well — +28.6 / +36.4